Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness

AIDS

Volumn 27, Issue SUIPPL.1, 2013, Pages

  Nanda, Kavita ^a   Delany Moretlwe, Sinead ^b   Dubé, Karine ^a   Lendvay, Anja ^a   Kwok, Cynthia ^a   Molife, Lebohang ^b   Nakubulwa, Sarah ^c   Edward, Vinodh A ^d   Mpairwe, Bernard ^c   Mirembe, Florence M ^c  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c MAKERERE UNIVERSITY   (Uganda)

^d AURUM INSTITUTE   (South Africa)

Author keywords

antiretroviral therapy; combined oral contraceptive pills; interaction; ovulation

Indexed keywords

CD4 ANTIGEN; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ADVERSE OUTCOME; ARTICLE; CELL COUNT; CELLULITIS; CONDOM USE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA; MENORRHAGIA; MENSTRUATION; OVULATION; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SELF REPORT; SEXUALLY TRANSMITTED DISEASE; SOUTH AFRICA; TREATMENT OUTCOME; UGANDA; VAGINA BLEEDING; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; OVULATION; PREGNANCY; PROSPECTIVE STUDIES; SOUTH AFRICA; UGANDA; YOUNG ADULT;

EID: 84885584529     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000050     Document Type: Article

References (15)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS; 2010.
2. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2006.
3. United Nations Department of Economic and Social Affairs. World Contraceptive Use 2011. New York: United Nations; 2011.
4. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007; 46:133-157.
5. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S8-S14.
6. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002; 29:471-477.
7. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr 2010; 55:473-482.
8. Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011; 58:e40-e43.
9. Panel on Antiretroviral Guidelines for Adult and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2011.
10. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kriengsinyot R, Ahluwalia J, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. J Acquir Immune Defic Syndr 2013; 62:534-539.
11. Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. HumReprod 2004; 19:2668-2673.
12. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003; 80:34-42.
13. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski G. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity. Eur J Contracept Reprod Healthcare 1996; 1:245-256.
14. Hou MY, Hurwitz S, Kavanagh E, Fortin J, Goldberg AB. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. Obstet Gynecol 2010; 116:633-640.
15. Steiner MJ, Kwok C, Dominik R, Byamugisha JK, Chipato T, Magwali T, et al. Pregnancy risk among oral contraceptive pill, injectable contraceptive, and condom users in Uganda, Zimbabwe, and Thailand. Obstet Gynecol 2007; 110:1003-1009. Development